glp 1 drug mechanism of action Science Behind GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements GLP-1 Promoting Foods - Quantity:3-Month Supply (90 servings) no-glp1

glp 1 drug mechanism of action Science Behind GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements GLP-1 Promoting Foods - Quantity:3-Month Supply (90 servings) no-glp1

GLP-1 Promoting Foods - Dr. Rachel Paul

GLP-1 receptor agonists may be appropriate for individuals who: Have a body mass index (BMI) of 35 kg/m² or higher (or lower thresholds—32.5 kg/m² or above—for people from Black, Asian, and other minority ethnic groups) and would benefit from weight loss Have established cardiovascular disease or are at high cardiovascular risk (certain GLP-1 receptor agonists have demonstrated cardiovascular benefits in clinical trials) Have chronic kidney disease (CKD) or heart failure, where specific agents may offer additional protection Require additional glucose-lowering therapy but wish to avoid weight gain associated with some other diabetes medicines Cannot tolerate or have contraindications to other glucose-lowering therapies NICE NG28 continuation criteria : GLP-1 receptor agonist therapy should be continued beyond 6 months only if the person has had a beneficial metabolic response , defined as a reduction of at least 11 mmol/mol (1.0%) in HbA1c and a weight loss of at least 3% of initial body weight

no-glp1

Quantity:3-Month Supply (90 servings)

⚖️ Making an Informed Choice: Comparing All Methods Choosing a path forward requires weighing the pros and cons of these distinctly different options